Understanding is what makes the advantage of AI real.
The results show where the sector stands on the AI Readiness Maturity Scale™, and the gap between what organisations understand of themselves and what AI sees of them, where they are in terms of fitness for AI Visibility.
Each organisation can see its own result, privately, via our partners or by
requesting a private briefing. Individual organisation results are not shared publicly.
01The 75 organisations.
The list is the population assessed: 75 current organisations, 15 in each of 5 regions: the United States, the United Kingdom, the European Union and Switzerland, Canada and Australia.
| Abbott Laboratories | US |
| AbbVie | US |
| AbCellera | Canada |
| Advanced Medical Solutions | UK |
| Amgen | US |
| Animalcare Group | UK |
| Ansell | Australia |
| Apotex | Canada |
| argenx | Netherlands |
| AstraZeneca | UK |
| Aurinia Pharmaceuticals | Canada |
| Australian Clinical Labs | Australia |
| Bausch + Lomb | Canada |
| Bausch Health | Canada |
| Bayer | Germany |
| BioNTech | Germany |
| BioSyent | Canada |
| Boehringer Ingelheim | Germany |
| Bristol Myers Squibb | US |
| Cipher Pharmaceuticals | Canada |
| Clinuvel Pharmaceuticals | Australia |
| Cochlear | Australia |
| Convatec | UK |
| CSL | Australia |
| Danaher | US |
| Eli Lilly and Company | US |
| Genmab | Denmark |
| Genus | UK |
| Gilead Sciences | US |
| GSK | UK |
| Haleon | UK |
| Healius | Australia |
| Hikma Pharmaceuticals | UK |
| Immunocore | UK |
| Integral Diagnostics | Australia |
| Jamieson Wellness | Canada |
| Johnson & Johnson | US |
| Knight Therapeutics | Canada |
| LivaNova | UK |
| Lonza | Switzerland |
| Mayne Pharma | Australia |
| Medexus Pharmaceuticals | Canada |
| Medtronic | Ireland |
| Merck & Co. | US |
| Merck KGaA | Germany |
| Mesoblast | Australia |
| Moderna | US |
| Nanosonics | Australia |
| Neuren Pharmaceuticals | Australia |
| NIOX Group | UK |
| Novartis | Switzerland |
| Novo Nordisk | Denmark |
| Oncolytics Biotech | Canada |
| Oxford Biomedica | UK |
| Oxford Nanopore Technologies | UK |
| Pfizer | US |
| PolyNovo | Australia |
| Pro Medicus | Australia |
| Profound Medical | Canada |
| Regeneron Pharmaceuticals | US |
| Roche | Switzerland |
| Sandoz | Switzerland |
| Sanofi | France |
| Siemens Healthineers | Germany |
| Smith+Nephew | UK |
| Sonic Healthcare | Australia |
| Stryker | US |
| Telix Pharmaceuticals | Australia |
| Theratechnologies | Canada |
| Thermo Fisher Scientific | US |
| Tristel | UK |
| UCB | Belgium |
| Vertex Pharmaceuticals | US |
| Xenon Pharmaceuticals | Canada |
| Zymeworks | Canada |
02Who leads.
The organisations placed in MONITOR, the top stage of the AI Readiness Maturity Scale™, are named here when the first results are published. They are the only organisations named with a result on this page. Each carries a link to its own results page: its position on the Scale, its Digital Doorway reading, and the corporate record it was assessed against.
All other organisations appear in the list above without a result. Their position is available to them privately, through the private briefing.
03Why AI readiness matters in life sciences.
Few sectors are as closely regulated, and few carry as much published material that must be right: prescribing information, patient leaflets, trial results, safety communications, regulatory filings and annual reports. AI systems now read that material, summarise it and answer with it, to clinicians, patients, investors and regulators, without asking whether a document is current.
At the same time the sector is expected to operate as efficiently as it can, and to embrace AI to do so: in research, in manufacturing, in how it reaches the people it serves. The 2 pressures meet in what has been published. An organisation that understands what AI sees of it can use AI to drive competitiveness while monitoring and protecting the value it has built. An organisation that does not is exposed on both counts: it cannot lead with AI on ground it has not examined, and it cannot show a regulator that what AI repeats in its name is under control.
AI readiness is the measure of how well an organisation stands up to that reading. Tracked across the sector on 1 measure, read from the outside in, it shows who is leading and who is lagging. It lets a board show it understands how AI represents the organisation, and that its exposure is being minimised, before a problem shows that it is not.
04What the results mean.
An organisation in the lower stages is an organisation AI struggles to read: information it cannot reach, cannot interpret, or finds in more than 1 version. The consequence is 1 of 2 things. AI passes the organisation over and answers with a competitor, or AI answers with confidence using material that is out of date or wrong. Neither is visible from inside the organisation, and both compound as more decisions begin with an AI answer.
An organisation in the upper stages is read accurately and consistently. Its published position is the position AI repeats. That is the position a board can defend.
79% of misinformation or misrepresentation has the organisation’s own online position as its root cause. AAAnow Research, Dec. 2023 to Jan. 2026; P&C (human misinformation) 2014 to 2023.
05Governance, and a defensible position.
Compliance here is the same work, done with evidence. Automation reads the estate as AI reads it, continuously: where the organisation stands on the AI Readiness Maturity Scale™, where misinformation is likely to arise, and which published material is causing it. That points remediation at the cause rather than the symptom.
It also produces a record: what was found, what was changed, and what AI reads now. A board asked how it manages AI risk can answer with a process it can show, repeated on a known cadence, rather than an assurance.
06The readings.
The sector’s results are published on this page. The AI Readiness position is the headline; Digital Doorway explains it.
How prepared the organisation’s published information is for AI: Foundations, Governance and Visibility, combined into 1 position and expressed on the AI Readiness Maturity Scale™, as ACT, OPTIMISE or MONITOR.
Whether the relevant AI routes can reach the organisation’s important information at all.
